Physician profile
Christopher J Bitetzakis
NPI 1275996241
$10,751.46
in general payments reported to CMS, 2019-2025
16 companies · $892 in 2025
The $892 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $219 · 2021: $277 · 2022: $954 · 2023: $4,921 · 2024: $3,489 · 2025: $892.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,524 · Travel and Lodging: $3,277 · Grant: $2,500 · Education: $1.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,523.75 |
| Travel and Lodging | $3,276.88 |
| Grant | $2,500.00 |
| Education | $1.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $3,893.42 | 2023-2024 | Mitraclip, Diamondback Coronary, Optis |
| Edwards Lifesciences Corporation | $3,251.52 | 2023-2025 | Pascal, Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Medtronic, INC. | $1,318.29 | 2022-2025 | Corevalve Evolut R, Micra |
| Boston Scientific Corporation | $505.36 | 2021-2025 | Watchman Flx |
| Ancora Heart, INC. | $415.57 | 2023 | Accucinch |
| Abiomed | $240.18 | 2023-2025 | Impella |
| Astellas Pharma US INC | $198.00 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $181.77 | 2023-2024 | Lifevest |
| Biotronik INC. | $169.96 | 2022 | |
| Cardiovascular Systems INC. | $168.90 | 2022 | |
| Baylis Medical Company INC | $154.11 | 2021 | |
| Philips North America LLC | $115.28 | 2023 | |
| Chiesi USA, INC. | $79.02 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.10 | 2019 | |
| Amgen INC. | $19.76 | 2023 | Repatha |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $19.22 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Bitetzakis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.